Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Artificial Intelligence (AI) can be a great tool in diagnosing and management of atopic dermatitis -- a chronic skin condition -- leading to more accurate, early, and standardised identification ...

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

In severe cases, atopic dermatitis is associated with sleep disturbances due to the pruritic rashes that appear on the skin during a flare-up, depression, anxiety, and loss of productivity ...

The most reported adverse reactions included fatigue, musculoskeletal pain, pruritus, rash and cough. The release states that the recommended dosage of subcutaneous nivolumab and hyaluronidase ...

The most common adverse reactions reported with Opdivo Qvantig were fatigue, musculoskeletal pain, pruritus, rash, and cough. Opdivo Qvantig is supplied in a single-dose vial containing nivolumab ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.